Wall Street analyst estimates for NEXGEL, Inc. (NXGL): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
NEXGEL, Inc. is a company that develops and produces advanced hydrogels and gels. These materials are characterized by their significant water content, aqueous polymer composition, and electron beam cross-linking technology. NEXGEL's diverse product range serves crucial applications across several sectors, including wound care management, medical diagnostic tools, transdermal drug delivery systems, and cosmetic formulations.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 1 |
| Avg rating (1-5) | 1.00 |
Valuation Ratios
| Price / Book | 0.45 |
| EV / EBITDA | -4.57 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2M | $2.0M | $2.2M | $717000 | $674000 | $1.6M | $2.0M | $4.1M | $8.7M | $11.4M |
| Cost of Revenue | $2.3M | $1.8M | $1.7M | $854000 | $965000 | $1.5M | $1.8M | $3.7M | $5.9M | $6.9M |
| Gross Profit | -$114000 | $147000 | $514000 | -$137000 | -$291000 | $8000 | $256000 | $374000 | $2.7M | $4.5M |
| Research & Development | 0 | 0 | 0 | 0 | 0 | $31000 | $367000 | $103000 | $78000 | $2000 |
| Selling, General & Admin | $1.8M | $1.1M | $2.4M | 0 | $2.0M | $2.4M | $2.8M | $3.4M | $5.9M | $7.9M |
| Operating Expenses | $1.8M | $1.1M | $2.4M | $1.8M | $2.0M | $2.6M | $3.6M | $3.9M | $6.3M | $7.9M |
| Operating Income | -$1.9M | -$969000 | -$1.9M | -$1.9M | -$2.3M | -$2.6M | -$3.3M | -$3.5M | -$3.6M | -$3.4M |
| EBITDA | -$1.5M | -$653000 | -$1.6M | -$1.9M | -$2.2M | -$2.2M | -$3.1M | -$2.7M | -$2.9M | -$2.1M |
| Interest Expense | 0 | 0 | 0 | 0 | $10000 | $2.0M | $1.3M | $15000 | $81000 | $34000 |
| Pre-tax Income | -$1.8M | -$969000 | -$1.9M | -$1.9M | -$2.3M | -$4.3M | -$4.7M | -$3.2M | -$3.5M | -$2.9M |
| Income Tax | -$63000 | -$16000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$1.8M | -$953000 | -$1.9M | -$1.9M | -$2.3M | -$4.3M | -$4.7M | -$3.2M | -$3.3M | -$3.0M |
| EPS | $-0.32 | $-0.17 | $-0.34 | $-0.35 | $-0.41 | $-0.77 | $-0.85 | $-0.56 | $-0.50 | $-0.38 |
| EPS (Diluted) | $-0.32 | $-0.17 | $-0.34 | $-0.35 | $-0.41 | $-0.77 | $-0.85 | $-0.56 | $-0.50 | $-0.38 |
| Shares Outstanding (Diluted) | $5.6M | $5.6M | $5.6M | $5.6M | $5.6M | $5.6M | $5.6M | $5.7M | $6.5M | $7.9M |
Price
| Price | $0.25 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ENLV · FEMY · GDTC · HBIO · IINN · MLSS · MTVA
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of NXGL: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks